Influence of serotonergic/noradrenergic gene polymorphisms on nausea and sweating induced by milnacipran in the treatment of depression

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 393-398

  Higuchi, Hisashi ^a   Takahashi, Hitoshi ^b   Kamata, Mitsuhiro ^c   Yoshida, Keizo ^d  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c AKITA UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Excessive sweating; Gene polymorphisms; Milnacipran; Nausea

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; MILNACIPRAN; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER;

ADULT; AGED; ANXIETY; ARTICLE; BITTER TASTE; BLURRED VISION; CHILL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HEART PALPITATION; HUMAN; HYPERHIDROSIS; INTRON; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MELANCHOLIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PATIENT COMPLIANCE; PHARMACOGENETICS; PROMOTER REGION; SIDE EFFECT; SKIN TINGLING; SLEEP DISORDER; STOMACH PAIN; SWEATING; TREMOR; URINARY HESITANCY; VARIABLE NUMBER OF TANDEM REPEAT; XEROSTOMIA;

EID: 70449714178     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull. 2001;57:161-178.
2. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10:732-747. (Pubitemid 41443048)
3. Mitchell AJ. Depressed patients and treatment adherence. Lancet. 2006;367(9528):2041-2043.
4. Kato M, Fukuda T, Wakeno M, et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology. 2006;53:186-195. (Pubitemid 44252779)
5. Sugai T, Suzuki Y, Sawamura K, Fukui N, Inoue Y, Someya T. The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J. 2006;6:351-356. (Pubitemid 44480155)
6. Yoshida K, Naito S, Takahashi H, et al. Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine. Neuropsychobiology. 2003;48:10-13. (Pubitemid 36928708)
7. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. (Pubitemid 9136500)
8. Sugawara Y, Higuchi H, Yoshida K, et al. Response rate obtained using milnacipran depending on the severity of depression in the treatment of major depressive patients. Clin Neuropharmacol. 2006;29:6-9. (Pubitemid 44378603)
9. Tajima O. Japanese experience with dual-action antidepressants. Int Clin Psychopharmacol. 2002;17(Suppl 1):S37-S42.
10. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987;334:1-100. (Pubitemid 17115352)
11. Higuchi H, Yoshida K, Takahashi H, et al. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients. Hum Psychopharmacol. 2003;18:255-259. (Pubitemid 36722310)
12. Ito K, Yoshida K, Sato K, et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res. 2002;111:235-239.
13. Sato K, Yoshida K, Takahashi H, et al. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology. 2002;46:136-140.
14. Yoshida K, Ito K, Sato K, et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:383-386. (Pubitemid 34038069)
15. Yoshida K, Naito S, Takahashi H, et al. Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:1279-1283. (Pubitemid 35341578)
16. Jonsson EG, Nothen MM, Gustavsson JP, et al. Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Psychiatry Res. 1998;79:1-9.
17. Marcy TR, Britton ML. Antidepressant-induced sweating. Ann Pharmacother. 2005;39:748-752.
18. Package insert. Lexapo (escitalopram oxalate). St. Louis, MO: Forest Pharmaceuticals; August 2004.
19. Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ. 1998;159:1245-1252. (Pubitemid 28554501)
20. Wickersham RM. Drug and comparisons 2004. 58th ed. St. Louis, MO: Wolters Kluwer Health; 2003. p. 1024-1071.
21. Butt MM. Managing antidepressant-induced sweating. J Clin Psychiatry. 1989;50:146-147.
22. Leeman CP. Pathophysiology of tricyclic-induced sweating. J Clin Psychiatry. 1990;51:258-259.
23. Morishita S, Arita S. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age. Hum Psychopharmacol. 2004;19:405-408. (Pubitemid 39172805)